Everand Logo

Welcome to Everand!

  • STAT

    3 China biotech stories to watch in 2019

    In 2018, biotech in China generated relentless news. What's next for 2019?
    by Rebecca Robbins Dec 26, 2018 2 minutes

    As 2019 begins, STAT reporters are taking a look at the stories they’re most eager to track during the year. Find all our “three to watch” series here. 

    This past year has often felt like the year that China’s biotech sector finally arrived. After years of punching below its weight, in 2018 the industry generated relentless news, milestones, and investment going in both directions across the Pacific.

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A 486% Drug Price Hike, AstraZeneca CEO Pay, And More
    Is there any circumstance when a 486% increase for a medicine might be justified? A small company called Harrow argues the case for an injectable eye treatment.
    STAT1 min read
    Disparities In Donor Acceptance Rates Point To Need For More Equitable Heart Transplant Care
    While access to donor hearts has increased, there are still gender- and race-based disparities in the acceptance rate of a donor heart offer by transplant teams, a new study finds.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Drug Shortages, Medicare Spending On An Alzheimer’s Drug, And More
    Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project.

    Related Books & Audiobooks